1000
Asia Pacific J Clin Nutr (1996) Vol5, No 1: 2-9
Asia Pacific J Clin
Nutr (1996) Vol5, No 1: 2-9
Intestinal flora and human health
Tomotari Mitsuoka, DVM, PhD
Professor Emeritus, The University
of Tokyo, Japan
There is a growing interest in intestinal flora
and human health and disease. The intestines of humans contain 100
trillion viable bacteria. These live bacteria, which make up 30%
of the faecal mass, are known as the intestinal flora. There are
two kinds of bacteria in the intestinal flora, beneficial and harmful.
In healthy subjects, they are well balanced and beneficial bacteria
dominate. Beneficial bacteria play useful roles in the aspects of
nutrition and prevention of disease. They produce essential nutrients
such as vitamins and organic acids, which are absorbed from the
intestines and utilised by the gut epithelium and by vital organs
such as the liver. Organic acids also suppress the growth of pathogens
in the intestines.
Other intestinal bacteria produce substances that
are harmful to the host, such as putrefactive products, toxins and
carcinogenic substances. When harmful bacteria dominate in the intestines,
essential nutrients are not produced and the level of harmful substances
rises. These substances may not have an immediate detrimental effect
on the host but they are thought to be contributing factors to ageing,
promoting cancer, liver and kidney disease, hypertension and arteriosclerosis,
and reduced immunity. Little is known regarding which intestinal
bacteria are responsible for these effects. A number of factors
can change the balance of intestinal flora in favour of harmful
bacteria. These include peristalsis disorders, surgical operations
of stomach or small intestine, liver or kidney diseases, pernicious
anaemia, cancer, radiation or antibiotic therapies, immune disorders,
emotional stress, poor diet and ageing.
However, more importantly, the normal balance of
intestinal flora may be maintained, or restored to a normal from
an unbalanced state, by oral bacterio-therapy or by a well balanced
diet. Oral bacterio-therapy using intestinal strains of lactic acid
bacteria, such as lactobacillus and bifidobacteria, can restore
normal intestinal balance and produce beneficial effects. Benefits
include suppression of intestinal putrification so as to reduce
constipation and other geriatric diseases; prevention and treatment
of diarrhoea including antibiotic-associated diarrhoea; stimulation
of the immune system; and increased resistance to infection.
Ecological
significance of intestinal flora
A single individual harbours in the intestine 100
trillion viable bacteria and so 1000 me 100 different bacterial species,
which constitute the intestinal flora. In mutual symbiotic or antagonistic
relationships, these organisms grow on ingested food components and
those secreted into the alimentary tract by the host, and excreted.
In the past, most of these organisms have been considered to be dead,
but marked advances in culturing techniques for anaerobic bacteria
enable cultivation of over 70% of the microscopic count of bacteria
in human faeces, and often more than 90%.
Major
bacterial groups composing the intestinal flora
The major bacterial groups detected in the intestinal
flora are roughly divided into the following three groups:
- the lactic acid bacteria group (LAB), including
Bifidobacterium, Lactobacillus and Streptococcus including
Enterococcus;
- the anaerobic group, including Bacteroidaceae,
anaerobic curved rods, Eubacterium, Peptococcaceae, Veillonella,
Megasphaera, Gemmiger, Clostridium, and Treponema; and
- the aerobic group, including Enterobacteriaceae,
Staphylococcus, Bacillus, Corynebacterium, Pseudo-monas, and
yeasts (Table 1) 1.
Development
of the intestinal flora of infants
The fetus exists in a sterile environment until birth.
After birth it rapidly becomes colonised by bacteria. On the 1st to
2nd days of life, the large intestine of neonates fed with breast
milk and supplementary cows milk is colonised by enterobacteriaceae,
streptococci including enterococci, and clostridia. On the 3rd day,
bacteroides, bifidobacteria and clostridia occur in 40% of infants.
Between days 4 and 7, bifidobacteria become predominant accounting
to 1010 to 1011 organisms per gram faeces, and
clostridia, bacteroides, enterobacteriaceae, streptococci, and staphylococci
decrease. Thus, nearly 100% of all bacteria cultured from stools of
breast-fed infants were bifidobacteria (Fig.1) 1.
Figure 1. Development
of the faecal flora of neonates.
Table 1. Differentiation of major intestinal bacterial
groups |
Bacterial group |
Gram-staining
|
Aerobic growth
|
Spore
|
Major fermentation products
|
LAB group |
|
|
|
|
Lactobacillus |
+
|
+
|
--
|
Lactic acid
|
Bifidobacterium |
+
|
--
|
--
|
Acetic acid + lactic acid
|
Streptococcus |
+
|
+
|
--
|
Lactic acid
|
Anaerobic group |
|
|
|
|
Bacteroidaceae |
--
|
--
|
--
|
Various products
|
Anaerobic curved
rods |
--
|
--
|
--
|
Succinic acid, butyric acid
|
Eubacterium |
+
|
--
|
--
|
Various products
|
Peptococcaceae |
+
|
--
|
--
|
Various products
|
Veillonella |
--
|
--
|
--
|
Acetic acid + propionic acid
|
Megasphaera |
--
|
--
|
--
|
Caproic acid + butyric acid
|
Gemmiger |
--
|
--
|
--
|
|
Clostridium |
+/--
|
--
|
+
|
Various products
|
Treponema |
--
|
--
|
--
|
|
Aerobic
group |
|
|
|
|
Enterobacteriaceae |
--
|
+
|
--
|
|
Staphylococcus |
+
|
+
|
--
|
|
Bacillus |
+
|
+
|
+
|
|
Corynebacterium |
+
|
+
|
--
|
|
Pseudomonas |
--
|
+
|
--
|
|
Yeasts |
+< 1000 /p>
|
+
|
--
|
|
|
Morphology |
|
|
The
intestinal flora of children and adults
Although bifidobacteria have been considered to be
the most important organisms for infants and lactobacilli and Escherichia
coli are more numerous bacteria for children and adults than bifidobacteria,
it has now become clear that bifidobacteria also constitute a member
of the major organisms in the colonic flora of healthy children and
adults. During weaning, when an adult diet is consumed, the stools
of infants shifted to the Gram-negative bacillary flora of adults:
bifidobacteria decrease by 1 log, the numbers of bacteroidaceae, eubacteria,
peptococcaceae, and usually clostridia outnumber bifidobacteria, which
constitute 5 to 10% of the total flora. The counts of enterobacteriaceae,
and streptococci decrease to less than 108 per gram faeces.
Lactobacilli, megasphaerae, and veillonellae are often found in adult
faeces, but the counts are usually less than 107 per gram
faeces. The species and biovars alter from infant-type such as B.
infantis and B. breve to adult-type such as B. adolescentis
and B. longum (Fig.2) 1.
Figure 2. Composition
of the faecal flora in adults.
The
intestinal flora of elderly persons
In elderly persons bifidobacteria decrease or diminish,
clostridia including C. perfringens significantly increase,
and lactobacilli, streptococci and enterobacteriaceae also increase.
This phenomenon is considered to be a result of ageing, but it might
accelerate senescence (Fig.3) 1.
Figure 3. Changes
in the faecal flora with increased age.
Disturbances
in the intestinal flora
Although the composition of the intestinal flora is
rather stable in healthy individuals, it can be altered by many endogenous
and exogenous factors such as peristalsic disorders, cancer, surgical
operations of stomach or small intestine, liver or kidney diseases,
pernicious anaemia, blind loop syndrome, radiation therapy, emotional
stress, disorders of immune systems, administration of antibiotics,
and ageing.
Disturbances in the intestinal flora are non-specific:
the small intestine harbours large numbers of bacteria, particularly
anaerobes, enterobacteriaceae and strepto-cocci; bifidobacteria disappear
or considerably decrease in the large intestine, while enterobacteriaceae
and strepto-cocci remarkably increase and, some times, Clostridium
perfringens also increase.
These ecological evidences would suggest that bifidobacteria should exist
in the large intestine for maintenance of health and are far more
important than Lactobacillus acidophilus as the beneficial
intestinal bacteria throughout human life. In other words, the reduction
or disappearance of bifidobacteria in human intestine would indicate
an "unhealthy" state.
Role
of the intestinal flora in human health
Metabolic
profile of the intestinal flora
The intestinal flora is composed of different bacterial
species, and thus, contains a variety of enzymes that perform the
extremely varied types of metabolism in the intestine, and influence
the hosts health and resistance to disease (Fig.
4). This includes such factors as: nutrition, physiological function,
drug efficacy, carcinogenesis, ageing, immunological response and
resistance to infection, endotoxins, and various other stresses. Within
the intestine, the bacteria are implicated in the conversion of various
substances that produce both beneficial and detrimental products to
the host. In addition, bacterial toxins and cell components produced
by some bacterial species modify the hosts immune responses,
enhancing or inhibiting immune function. The beneficial intestinal
flora protect the intestinal tract from proliferation or infection
of harmful bacteria, while the detrimental bacteria manifest pathogenicity
when the hosts resistance is decreased.
Figure 4. Enzymatic
activities of intestinal bacteria.
The intestinal flora may play an
important role in the causation of cancer and ageing
Dietary factors are considered important environmental
risk determinants for colorectal cancer development. From epidemiological
observations, a high fat intake is associated positively and a high
fibre intake negatively with colorectal cancer. This is thought to
occur by the following mechanisms. From food components in the gastrointestinal
tract, organisms produce various carcinogens from the dietary components
and endogenous substances, detoxify carcinogens, or enhance the hosts
immune function, which results in changes in the incidence of cancers.
The ingestion of large amounts of animal fat enhances bile secretion,
causing an increase in bile acid and cholesterol in the intestine.
These increased substances are converted by intestinal bacteria into
secondary bile acids, their derivatives, aromatic polycyclic hydrocarbons,
oestrogen and epoxides derivatives that are related to carcinogenesis.
Various tryptophan metabolites (indole, skatole, 3-hydroxykinurenine,
3-hydroxyanthranilic acid, etc.) phenols, amines, and nitroso compounds
produced by intestinal bacteria from protein also participate in carcinogenesis
(Fig. 5). However, some intestinal bacteria reportedly inactivate noxious
substances in the intestine.
Figure 5. Relationships
among diet, intestinal bacteria and cancer.
Recent epidemiological studies have revealed that
insufficient intake of dietary fibre is associated with high incidences
of Western dis 1000 eases such as colorectal cancer, obesity, heart
disease, diabetes, and hypertension. Ingested dietary fibre causes
increased volume of faeces, dilution of noxious substances, and shortening
of the transit time of intestinal contents, resulting in early excretion
of noxious substances such as carcinogens produced by intestinal bacteria.
The cell components of intestinal bacteria modify
the hosts immune function; some enhance immune response and
others suppress it, involving them indirectly in the suppression or
enhancement of carcinogenesis.
It is completely unknown at present which of these
mechanisms plays the key role in carcinogenesis. Our studies with
gnotobiotic mice showed that the presence of bacteria in the intestine
can have marked effect on the incidence of liver tumours in C3H/He
mice. Mice with conventional microflora had a much higher incidence
of hepatic tumours (about 75% after 1 year) than their germfree counterparts
(30% incidence after 1 year).
Table 2. Incidence
of liver tumour in germfree (GF), conventionalised (CV), and gnotobiotic
(GB) C3H/He male mice associated with human intestinal bacteria
Group |
Bacteria
|
NB
|
Liver tumour (%)*
|
GF |
Germfree |
0
|
30
|
CV |
Conventionalised
|
|
75
|
GB6 |
Mitsuokella
multiacida A4052 |
9.7
|
75
|
GB2 |
Enterococcus
faecalis M266TA |
9.7
|
67
|
GB1 |
Escherichia
coli M66 |
10.3
|
62
|
GB13 |
Bifidobacterium
longum E194b |
10.1
|
47
|
GB20 |
Escherichia
coli M66 |
10.2
|
100
|
|
Enterococcus
faecalis M266TA |
10.2
|
|
|
Clostridium
paraputrificum VPI1586 |
9.5
|
|
|
Clostridium
paraputrificum VP16558
|
|
|
GB7 |
Escherichia
coli M66 |
9.9
|
88
|
|
Clostridium
perfringens MAC521 |
9.5
|
|
GB9 |
Escherichia
coli M66 |
9.7
|
80
|
1000
|
Enterococcus
faecalis M266TA |
9.9
|
|
|
Bacteroides
vulgatus M45 |
10.1
|
|
GB21 |
Escherichia
coli M66 |
9.3
|
46
|
|
Enterococcus
faecalis M266TA |
10.2
|
|
|
Clostridium
paraputrificum VPI1586 |
9.6
|
|
|
Clostridium
paraputrificum VP16558 |
|
|
|
Bifidobacterium
longum E194b |
9.8
|
|
NB= number of bacteria established
log/g faeces ; * = percentage of animals
|
Table 3. Comparison of lifespan
of germfree (GF) conventional (CV) female mice and gnotobiotic
(GB) CF#1 female mice associated with human intestinal bacteria.
|
Animals
|
Bacterial strains
used |
GF
|
CV
|
GB-1
|
GB-2
|
GB-3
|
Bifidobacterium
longum E194b |
--
|
*
|
9.8a
|
--
|
9.8
|
Clostridium
perfringens MAC521 |
--
|
*
|
8.6
|
8.6
|
-- 1000 font>
|
Escherichia
coli 123 |
--
|
*
|
9.1
|
10.0
|
9.4
|
Enterococcus
faecalis 1-12 |
--
|
*
|
10.1
|
10.1
|
10.1
|
Bacteroides
vulgatus M-64 |
--
|
*
|
10.3
|
10.1
|
10.3
|
Eubacterium
aerofaciens 151 |
--
|
*
|
10.3
|
10.3
|
10.3
|
Lifespan |
96.3
|
78.2
|
87.1
|
80.7
|
87.1
|
(Means ± SD of age in weeks) |
± 14.6
|
± 22.2
|
± 19.9
|
± 21.5
|
± 17.6
|
*: Conventional rat flora. a: No. of bacteria
established (log/ g faeces)
|
Furthermore, when germfree mice were contaminated
with specific intestinal bacteria, isolated from humans, the tumour
incidence ranged up to 100%; of the mono-contaminated mice Mitsuokella
multiacidatumours in 75% of the mice, Enterococcus faecalis
gave in 67%, Escherichia coli in 62%, and B. longum
in 47%. When mixtures of strains were used, high rates of tumour production
were observed with mixtures of E. coli + E. faecalis +
C. paraputrificum (100%), coli + C. per-fringens (88%),
or E. coli + E. faecalis + B. E. vulgatus(80%).
However, this promoting effect was suppressed by 46% by the addition
of Bifidobacterium longum to the first promoting combination (Tabl
1000 e 2) 3,4.
We also studied the effect of intestinal flora on
longevity. Germfree (GF) mice, conventional mice, and gnotobiotic
(GB) mice (GB-1) associated with E. coli, Enterococcus faecalis,
Bacteroides vulgatus, Eubacterium aerofaciens, Bifidobacterium longum
and Clostridium perfringens, and those associated with the
same combination of intestinal bacteria without B. longum (GB-2)
or C. perfringens (GB-3) were produced, and maintained until
their natural death (Table 3). Average life spans of GF female were
longest, 96.3 weeks, 78.2 weeks in CV, 87.1 weeks in GB-1, 80.7 weeks
in GB-2, and 87.1 weeks in GB-3: the average life spans were shorter
in GB-2 than in GF. There was also no difference in average life spans
between GB-1 and GB-3. These findings suggest that the presence of
B. longum may be related to longevity in GB animals.
These two studies suggested that intestinal bacteria
are related to both promotion and prevention of cancer and ageing.
The mechanism of the suppressive effect of bifidobacteria on liver
tumours might be related to detoxifying carcinogens by bifidobacteria.
Dietary
control of intestinal flora for human health
Evidence that the intestinal flora is closely related
to the hosts health and disease indicates the importance of
the balance of the intestinal flora for health and longevity. In other
words, the increase of harmful bacteria in the intestine may ultimately
lead to various disorders, such as liver and kidney disorders, atherosclerosis,
hypertension, cancer, and ageing. A satisfactory balance of the intestinal
flora is possibly achieved by a nutritionally varied diet, and inclusion
of dietary fibre and fermented milk which promote useful bacteria
or suppress harmful bacteria.
Effect of intake of dietary fibre
or oligosaccharides
Human digestive enzymes have little or no effect on raw starch
and polysaccharides such as cellulose, pectin, hemicellulose, and
pentosan; and oligosaccharides such as melibiose, raffinose, stachyose,
fructo-oligosaccharides, isomalto-oligosaccharides, and galacto-oligosaccharides.
These substances are hydrolysed to varying degrees and digested by
colonic bacteria with the production of organic acids, mainly volatile
fatty acids (acetate, propionate, and butyrate), and gas (carbon dioxide
and hydrogen). Small amounts of lactic, formic and succinic acids
are also produced. Methane may be produced in some people.
Figure 6. Changes
in faecal bifidobacteria by the administration of FOS. FOS (8g/ day)
were administered to aged subjects.
Most Bifidobacterium species metabolise a wide
rage of indigestible polysaccharides and oligosaccharides to acetic
and lactic acids and subsequently act as effective scavengers in the
large intestine, when many oligosaccharides are ingested in the diet,
while E. col 1000 i and C. perfringens do not.
In this way several commercially available oligosaccharides
including raffinose, stachyose, fructo-oligosaccharides, isomalto-oligosaccharides,
galacto-oligosaccharides are effective for proliferation of resident
or implanted bifidobacteria in intestine and cause the reduction of
faecal ammonia and pH as well as serum cholesterol and triglyceride
level of the host5-8.
In our studies with volunteers, improvement of intestinal
flora as well as intestinal environment were observed by oral administration
of various oligosaccharides, including fructo-oligosaccharides, palatinose
condensate, raffinose, and soybean oligosaccharides. Table 4 shows
utilisation of five oligosaccharides by intestinal bacteria. Most
of the oligosaccharides stimulated the growth of bifidobacteria in
vitro and in vivo (Fig.6), and caused reduction of faecal pH, beta-glucuronidase, azoreductase,
and indole, serum cholesterol and triglycerides levels as well as
the blood pressure of elderly patients with hyperlipidaemia. From
the results presented here, it may be concluded that oligosaccharides
are considered to enhance the intestinal bifidobacteria, to promote
the intestinal flora, the consistency of stool, and lipid metabolism.
We also studied the effect of dietary fibre on the
faecal flora and faecal metabolite in eight healthy adult volunteers
fed with low cholesterol (LC) diet, high cholesterol (HC) diet and
high cholesterol supplemented with polydextrose (15g/day) (HC-P) diet
for a 12 day interval. While a decrease (ca. 25%) of the faecal weight
was observed during HC diet, HC-P diet led to a ca. 30% increase of
the faecal weight. The faecal pH increased (ca. 0.2) during HC diet
and decreased (ca. 0.6) during HC-P diet. Faecal putrefactive products
including phenol, p-cresol, indole, iso-butyric and iso-valeric acids
remarkably decreased by the administration of polydextrose (Fig. 7). In addition, the occurrence of clostridia, including Clostridium
perfringens was higher during HC diet than during HC-P diet. These
results suggested that polydextrose has a beneficial effect on the
intestinal environment and human health through changing the balance
and metabolic activity of the intestinal flora and physiologic activity
of the host and that intestinal clostridia are involved in putrefactive
activity in the intestinal content9.
Effect of yoghurt on human health
Yoghurt and other fermented milk products may enhance
human health by the following mechanisms10.
- Effect of milk used for yoghurt production: Milk
protein prevents stomach cancer. Lactose increases indigenous bifidobacteria
in the intestine. Calcium and iron prevent osteoporosis and anaemia,
respectively. Vitamin A may prevent certain cancers.
- Effect of fermentation products of yoghurt: Lactate
prevents constipation and inhibits putrefactive bacteria. Peptone
and peptides promote liver function.
Effect of lactic acid bacteria (LAB): LAB detoxify carcinogens,
stimulate immune response, and lower serum cholesterol.
Several recent studies have focused on bifidobacteria
to establish the importance of these bacteria in influencing certain
normal functions of the intestinal tract and in exploring its role
in human health and diseases. In Japan, bifidobacteria now-a-days
have been used as dietary supplements or as starter culture for yoghurt
and other cultured milk products with the thought that such products
may help the promotion of health. The effects of the daily intake
of such products are reported as follows:
- to suppress the putrefactive bacteria as well as
intestinal putrefaction, for the prevention of constipation, geriatric
diseases, including cancer,
- to prevent and treat antibiotic-associated diarrhoea,
- to stimulate immune response,
- to contribute to a greater resistance to infection.
Figure 7. Influence
of low cholesterol (LC) diet, high cholesterol (HC) diet supplemented
with polydextrose. (HCP) on b -glucoronidase,
b -glucosidase, nitro-reductase
and tryptophanase activity in human faeces.
Effect of oral administration of
bifidobacteria on intestinal flora and intestinal metabolites
We observed that oral administration of 109
Bifidobacterium longum preparation per day for 5 weeks to 5
healthy volunteers from 25 to 35 years old resulted in the increase
of the counts of bifidobacteria and the remarkable decrease of the
counts and frequencies of occurrence of clostridia in stools. This
result also reflected a decrease of ammonia concentration and beta-glucuronidase
activity in both faeces and serum11.
Serum cholesterol in Hartley male rabbits fed with
0.25% cholesterol diet supplemented with 1010/day of B.
longum for 13 weeks were compared with the control diet group.
In 2 of 3 rabbits fed with diet supplemented with B. longum
there was a remarkably suppressed increase in cholesterol level, but
1 of 3 rabbits showed no effect.
Table 4. Utilisation of 5 sugars by various intestinal
bacteria.
Bacterial species |
Number of strains
|
SOR
|
RAF
|
STA
|
FOS
|
GLU
|
Bifidobacterium: |
|
|
|
|
|
|
B. bifidum |
6
|
--
|
--
|
±
|
--
|
++
|
B. longum |
8
|
+++
|
++
|
+++
|
++
|
+++
|
B. breve |
4
|
+++
|
+++
|
+++
|
+
|
+++
|
B. infantis |
2
|
+++
|
+++
1000 |
+++
|
++
|
+++
|
B. adolescentis |
9
|
++
|
++
|
++
|
++
|
+++
|
Lactobacillus: |
|
|
|
|
|
|
L. casei |
2
|
--
|
--
|
--
|
--
|
+
|
L. acidophilus |
3
|
±
|
±
|
±
|
+
|
++
|
L. gasseri |
1
1000 |
+
|
+
|
--
|
+
|
+
|
L. salivarius |
2
|
++
|
++
|
++
|
+
|
++
|
Bacteroides: |
|
|
|
|
|
|
B. vulgatis |
9
|
±
|
±
|
+
|
+
|
++
|
B. fragilis |
3
|
+
|
+
|
+
|
+
|
++
|
1000
B. distasonis |
5
|
+
|
±
|
+
|
±
|
+
|
B. ovatus |
4
|
+
|
+
|
+
|
+
|
++
|
B. thetaiotamicron |
2
|
±
|
±
|
±
|
+
|
+
|
B. uniformis |
1
|
+
|
+
|
+
|
+
|
+
|
B. melaninogenicus |
1
|
+
|
+
|
+
|
+
|
+
|
Fusobacterium: |
|
|
|
|
|
|
F. varium |
1
|
--
|
--
|
--
|
--
|
±
|
F. necrophorum |
1
|
--
|
--
|
--
|
--
|
--
|
Mitsuokella
multiacida |
4
|
++
|
++
|
++
|
+
|
++
|
1000
Megamonas
hypermegas |
1
|
++
|
++
|
++
|
+
|
+++
|
Eubacterium: |
|
|
|
|
|
|
E. limosum |
3
|
--
|
--
|
--
|
±
|
++
|
E. aerofaciens |
2
|
±
|
±
|
±
|
±
|
++
|
E. nitritogenes |
1
|
--
|
--
|
--
|
--
|
++
|
E. lentum |
1
|
--
|
--
|
--
|
--
|
--
|
Clostridium: |
|
|
|
|
|
|
C. perfringens |
6
|
--
|
--
|
--
|
--
|
+
|
C. paraputrificum |
4
|
--
|
--
|
--
|
--
|
+++
|
C. difficile |
4
|
--
|
--
|
--
|
--
|
+
|
C. butyricum |
2
|
++
|
++
|
++
|
++
|
+++
|
C. clostridiforme |
2
|
±
|
±
|
±
|
--
|
+
|
C. innocuum |
1
|
--
|
--
|
--
|
±
|
+++
|
C. ramosum |
1
|
±
|
+
|
±
|
++
|
+++
|
C. sordelli |
1
|
--
|
--
|
--
|
--
|
±
|
C. septicum |
1
|
--
|
--
|
--
|
--
|
+++
|
C. cadaveris |
1
|
--
|
--
|
--
|
--
|
±
|
C. sporogenes |
1
|
--
|
--
|
--
|
--
|
1000
±
|
Propionibacterium
acnes |
1
|
--
|
--
|
--
|
--
|
++
|
Peptostreptococcus: |
|
|
|
|
|
|
P. magnus |
1
|
--
|
--
|
--
|
--
|
--
|
P. anaerobius |
1
|
--
|
--
|
--
|
--
|
±
|
P. productus |
2
|
±
|
±
|
±
|
+
|
++
|
P. asaccharolyticus |
1
|
--
|
--
|
--
|
--
|
±
|
P. prevotti |
1
|
±
|
±
|
±
|
--
|
+
|
Veillonella: |
|
|
|
|
|
|
V. dispar |
1
|
--
|
--
|
--
|
--
|
--
|
V. parvula |
1000
2
|
--
|
--
|
--
|
--
|
--
|
Megashaera
elsdenii |
1
|
--
|
--
|
--
|
--
|
±
|
Escherichia
coli |
6
|
--
|
±
|
--
|
--
|
++
|
Klebsiella
pneumoniae |
3
|
+
|
+
|
+
|
+
|
++
|
Enterobacter
aerogenes |
1
|
< 1000 p align="center">+
|
±
|
±
|
±
|
±
|
Enterococcus |
|
|
|
|
|
|
E. faecalis |
1
|
±
|
±
|
±
|
+
|
+++
|
E. faecium |
1
|
+
|
±
|
+
|
+
|
+++
|
Streptococcus
pyogenes |
1
|
--
|
--
|
--
|
± <
|
|